VAVictor Javier Avila-Quintero

Victor Javier Avila-Quintero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victor Javier Avila-Quintero has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations between childhood interactions with people of Black race/ethnicity and racial implicit association tasks in psychiatric providers in the United States – a cross‐sectional study

    by Victor J. Avila‐Quintero, Katie Malison, Miciah Wilkerson, José M. Flores, Jerome H. Taylor, Angeli Landeros‐Weisenberger, Michael H. Bloch, Amalia Londoño Tobón

    Background: We estimated associations between psychiatric providers' self‐reported amount and valence of interaction with individuals of Black race/ethnicity during childhood and three implicit association tests (IATs) scores. Valence of interaction refers to the positive or negative nature of childhood interactions, capturing whether these interactions were reported as generally favorable or unfavorable. Methods: In a cross‐sectional study, psychiatric providers and trainees reported the amount and valence of interaction with (1) individuals of Black race/ethnicity during childhood, (2) colleagues, and (3) patients of Black race/ethnicity during medical practice. Providers also completed three IATs pairing Black or White faces and terms about psychiatric diagnosis, compliance, and treatment. Linear and logistic regression models estimated relationships between IAT D ‐scores and ratings of interaction amount and valence with individuals of Black race/ethnicity. Results: Among 294 providers (medical students, residents, fellows, and board‐certified psychiatrists), increased self‐reported amount (β Δ Compliance = −.08, p < .01 and β Δ Treatment = −.09, p < .001) and valence (β Δ Compliance = −.08, p < .01 and β Δ Treatment = −.08, p < .01) of childhood interaction with individuals of Black race/ethnicity were significantly associated with lower D ‐scores on IAT tasks. In contrast, ratings of amount and valence of recent interaction with colleagues and patients of Black race/ethnicity were not statistically associated with IAT D ‐scores. Conclusions: While amount and valence of interaction between providers and individuals of Black race/ethnicity during childhood were associated with lower implicit association scores, recent interactions with colleagues and patients of Black race/ethnicity were not significantly associated with implicit associations. Emerging research suggest that lower IAT D ‐scores may be associated with more unbiased behaviors and decisions in clinical settings. Considering this, our findings suggest that early‐life interactions with individuals of Black race/ethnicity may influence implicit biases in adulthood, with potential implications for reducing racial disparities in psychiatric care. However, further research is needed to confirm these relationships and fully understand their impact in clinical contexts.

  • Response to the letter to the editor

    by Thomas Hickey, Victor Javier Avila-Quintero, Joao P De Aquino

  • Open Access

    Buprenorphine versus full agonist opioids for acute postoperative pain management: an infographic

    by Thomas R Hickey, Gabriel P A Costa, Victor Javier Avila-Quintero, Joao P De Aquino

    Opioids continue to play a role in postoperative pain management and continue to result in predictable harm to patients including persistent use and overdose.1 Buprenorphine, a partial agonist opioid, has an almost 60-year track record of efficacy in acute pain management. However, in contemporary practice, it is rarely used for this purpose and is better known as an essential medicine for opioid use disorder. In this systematic review and meta-analysis of randomized controlled trials, the authors aimed to broaden the understanding of buprenorphine’s efficacy versus opioids as a class in the treatment of acute postoperative pain in adults. Inclusion criteria were met for 58 studies.


  • Top Cited Papers

    Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials

    by Thomas R Hickey, Gabriel P A Costa, Debora Oliveira, Alexandra Podosek, Audrey Abelleira, Victor Javier Avila-Quintero, Joao P De Aquino

    Background/Importance: Opioids continue to play a key role in managing acute postoperative pain, but their use contributes to adverse outcomes. Buprenorphine may offer effective analgesia with a superior safety profile. Objective: To compare the efficacy and safety of buprenorphine with other opioids for acute postoperative pain management in adults. Evidence review: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to February 2024. Randomized controlled trials comparing buprenorphine with other opioids for acute postoperative pain management in adults were included. Of 2421 records identified, 58 studies met inclusion criteria. Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analysis was performed using Stata/BE V.18. The primary outcome was pain intensity. Secondary outcomes included rescue analgesia use, duration of analgesia, and adverse effects. Findings: Analysis of 41 comparisons (2587 participants) showed buprenorphine significantly reduced pain intensity compared with all other opioids (Hedges’s g=−0.36, 95% CI=−0.59 to −0.14, p2 =86.28%, 95% CI=81.55% to 88.99%) and moderate for rescue analgesia (I 2 =38.93%, 95% CI=1.44% to 64.37%). Risk of bias was low in 19 studies, with some concerns in 37 studies, and high in two studies. Conclusions: Buprenorphine demonstrated superior efficacy in managing acute postoperative pain compared with FAOs, with a favorable safety profile and longer duration of action. These findings support the use of buprenorphine as a first-line opioid analgesic for acute postoperative pain management requiring opioid analgesia, potentially reducing opioid-related harm in the postoperative period. PROSPERO registration number: CRD42023447715.


  • Racial Implicit Associations in Child Psychiatry

    by Katie A. Malison, Victor J. Avila-Quintero, Cheryl S. Al-Mateen, José Flores, Angeli Landeros-Weisenberger, Wanjikũ F.M. Njoroge, Douglas K. Novins, Barbara Robles-Ramamurthy, Jerome H. Taylor, Michael H. Bloch, et al.


  • Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression

    by Alice Lineham, Victor J. Avila-Quintero, Michael H. Bloch, Jennifer Dwyer

    Objective: Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods: We conducted a secondary data analysis of adolescents who participated in a randomized, single-dose, midazolam-controlled crossover trial of ketamine for adolescents with treatment-resistant depression. We examined the relationship between 19 exploratory demographic and clinical variables and depression symptom improvement (using the Montgomery-Åsberg Depression Rating Scale [MADRS]) at 1 and 7 days postinfusion. Results: Subjects who had fewer medication trials of both antidepressant medications and augmentation treatments were more likely to experience depression symptom improvement with ketamine. Subjects with shorter duration of their current depressive episode were more likely to experience depression symptom improvement with ketamine. Subjects currently being treated with selective serotonin reuptake inhibitor medications, and not being treated with serotonin–norepinephrine reuptake inhibitor medications, also experienced greater symptom improvement with ketamine. When receiving the midazolam control, less severe depressive symptoms, as measured by the Children's Depression Rating Scale (CDRS) (but not MADRS), and a comorbid attention-deficit/hyperactivity disorder diagnosis were associated with increased response. Conclusions: Findings should be viewed as preliminary and exploratory given the small sample size and multiple secondary analyses. Identifying meaningful predictors of ketamine response is important to inform future therapeutic use of this compound, however, considerably more research is warranted before such clinical guidance is established. The trial was registered in clinicaltrials.gov with the identifier NCT02579928.


  • Association Between Patient Race and Ethnicity and Outcomes With COVID-19: A Retrospective Analysis From a Large Mid-Atlantic Health System

    by Anirudh Rao, Muhtadi H. Alnababteh, Victor J. Avila-Quintero, Jose M. Flores, Nina E. Laing, David A. Boyd, Jennifer Yu, Naheed Ahmed, Hunter Groninger, Akram M. Zaaqoq

    Background: Members of racial and ethnic minority groups have been disproportionately impacted by coronavirus-2019 (COVID-19). The objective of the study is to describe associations between race and ethnicity on clinical outcomes such as need for mechanical ventilation and mortality. Methods: Retrospective cohort study of patients with severe COVID-19 infection admitted within a large, not-for-profit healthcare system in the mid-Atlantic region between March and July, 2020. Patient demographic data and clinical outcomes were abstracted from the electronic health record. Logistic regressions were performed to estimate associations between race and ethnicity and the clinical outcomes. Results: The study population (N = 2931) was stratified into 1 of 3 subgroups: non-Hispanic White (n = 466), non-Hispanic Black (n = 1611), and Hispanic (n = 654). The average age of White, Black, and Hispanic patients was 69 ± 17.06, 64 ± 15.9, and 50 ± 15.53 years old, respectively ( P < .001). Compared to White patients, Black and Hispanic patients were at increased odds of needing mechanical ventilation due to COVID-19 pneumonia (odds ratio [OR] Black = 1.35, 95% confidence interval [CI] = 1.04 to 1.75, P < .05; OR Hispanic = 1.43, 95% CI = 1.06 to 1.93, P < .05). When compared to White patients, Hispanic patients were at decreased odds of death (OR = 0.45, 95% CI = 0.32 to 0.63, P < .001). However, when adjusting for age, there were no statistically significant differences in the odds of death between these groups (adjusted OR [aOR] Black = 1.05, 95% CI = 0.80 to 1.38, P = .71; aOR Hispanic = 1.10, 95% CI = 0.76 to 1.60, P = .62). Conclusion: Our analysis demonstrated that Hispanic patients were more likely require mechanical ventilation but had lower mortality when compared to White patients, with lower average age likely mediating this association. These findings emphasize the importance of outreach efforts to communities of color to increase prevention measures and vaccination uptake to reduce infection with COVID-19.


  • Open Access

    Does the SDMQ-9 Predict Changes in HbA1c Levels? An Ecuadorian Cohort

    by María José Farfán Bajaña, Jorge Moncayo-Rizzo, Geovanny Alvarado-Villa, Victor J. Avila-Quintero

    Background and Objectives: Diabetes mellitus affects 422 million people around the world, positioning it as a major health problem. According to the WHO(World Health Organization), 90% corresponds to type 2. The shared-decision making (SDM) is a method used to facilitate patient control, medication, maintenance, and assessment of health status according to their priorities and preferences. With the application of SDM in patients with diabetes, it is expected there will be an increase in treatment adherence and a reduction in HbA1c levels. The aim of this study is to determine the predictors of the change in HbA1c. Material and Methods: A sample of 76 participants attending as endocrinology outpatients was obtained. Data collected within the sample included: sex, age, educational level, body mass index, and the level of SDM using the SDMQ-9. In addition, HbA1c levels were measured twice: at baseline and three months after the first measurement. Results: The linear regression indicates that the level of SDM is a significant predictor of the change in HbA1c, specifically in men. However, the direction of the relationship was a somewhat opposite trend than we expected. Higher levels of SDM imply an increase in HbA1c rather than a reduction. Conclusions: Contrary to the literature, our results shows that elevated levels of perceived SDM may be associated with worse diabetic control. However, more investigation is needed as these results are not generalizable, due to the specific population used and the sample size. Furthermore, to better understand the effect of SDM on the change in HbA1c in patients with poorly controlled diabetes.

  • The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis

    by Luis C. Farhat, José M. Flores, Emily Behling, Victor J. Avila-Quintero, Adam Lombroso, Samuele Cortese, Guilherme V. Polanczyk, Michael H. Bloch

    Clinical guidelines currently recommend practitioners titrate stimulant medications, i.e., methylphenidate (MPH) and amphetamines (AMP), to the dose that maximizes symptom control without eliciting intolerable adverse events (AEs) when treating attention-deficit/hyperactivity disorder (ADHD) in school-aged children/adolescents. However, robust evidence-base regarding the effects of doses and dosing strategies of stimulants on clinical outcomes in the treatment of children/adolescents with ADHD is currently lacking and stimulants are often underdosed in clinical practice. To address this gap and provide rigorous evidence-base in relation to the dose and dosing strategy of stimulants, we conducted the largest systematic review and dose–response meta-analysis examining change in ADHD symptoms (efficacy), and treatment discontinuations due to AEs (tolerability) and any reason (acceptability). We conducted one-stage random-effects dose–response meta-analyses examining MPH and AMP separately, stratifying trials based on fixed-dose and flexible-dose design. Daily doses of stimulants were converted to MPH- and AMP-equivalent doses by adjusting for different pharmacokinetics across formulations. We also conducted pairwise meta-analyses to provide indirect comparisons between flexible-dose versus fixed-dose trials. Our study included 65 RCTs involving 7 877 children/adolescents. Meta-analyses of fixed-dose trials for both MPH and AMP demonstrated increased efficacy and increased likelihood of discontinuation due to AEs with increasing doses of stimulants. The incremental benefits of stimulants in terms of efficacy decreased beyond 30 mg of MPH or 20 mg of AMP in fixed-dosed trials. In contrast, meta-analyses of flexible-dose trials for both MPH and AMP demonstrated increased efficacy and reduced likelihood of discontinuations for any reason with increasing stimulant doses. The incremental benefits of stimulants in terms of efficacy remained constant across the FDA-licensed dose range for MPH and AMP in flexible-dose trials. Our results suggest that flexible titration as needed, i.e., considering the presence of ADHD symptoms, and tolerated, i.e., considering the presence of dose-limiting AEs, to higher doses of stimulants is associated with both improved efficacy and acceptability because practitioners can increase/reduce doses based on control of ADHD symptoms/dose-limiting AEs. Although fixed-dose trials that are required by the FDA are valuable to characterize dose-dependency, they may underestimate the true potential benefit of trialing dose-increases of stimulants in clinical practice by not allowing dose adjustment based on response and tolerability. Additional research is required to investigate potential long-term effects of using high doses of stimulants in clinical practice.


  • Pharmacological and somatic treatment effects on suicide in adults: A systematic review and meta‐analysis

    by Samuel T. Wilkinson, Daniel Trujillo Diaz, Zachary W. Rupp, Anubhav Kidambi, Karina L. Ramirez, José M. Flores, Victor J. Avila‐Quintero, T. Greg Rhee, Mark Olfson, Michael H. Bloch

    Background Suicide is a public health crisis. We conducted a systematic review and meta-analysis of the effects of psychopharmacologic and somatic therapies on suicide risk. Methods A systematic search of MEDLINE for studies evaluating the effects of pharmacologic (excluding antidepressants) or somatic interventions on suicide risk was conducted. Studies were included if they used a comparison group, reported on suicide death, assessed a psychopharmacological or somatic intervention, and included adults. Study quality was assessed using the Newcastle–Ottawa scale. Fifty-seven studies were included from 2940 reviewed citations. Results In bipolar disorder, lithium was associated with a reduction in the odds of suicide compared to active controls (odds ratio [OR] = .58, p = .005; k = 12) and compared to placebo/no lithium (OR = .46, p = .009; k = 9). In mixed diagnostic samples, lithium was associated with a reduction in the odds of suicide compared to placebo/no lithium (OR = .27, p < .001; k = 12), but not compared to active controls (OR = .89, p = .468; k = 7). In psychotic disorders, clozapine was associated with a reduction in the odds of suicide (OR = .46, p = .007; k = 7). Associations between suicide death and electroconvulsive therapy (OR = .77, p = .053; k = 11), non-clozapine antipsychotics in bipolar disorder (OR = .73, p = .090; k = 6) and antipsychotics in psychotic disorders (OR = .39, p = .069; k = 6) were not significant. There was no consistent relationship between antiepileptic mood stabilizers and suicide. There were insufficient studies to meta-analyze associations of suicide risk with vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, or transcranial direct current stimulation. Conclusion Lithium and clozapine have consistent data supporting protective effects against suicide in certain clinical contexts.